In this episode, I’ll discuss the first update to the Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU.
Published recently in the journal Critical Care Medicine is the first update to the Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU. Of the 9 updates, 7 relate to pharmacotherapy:
1. For adults with severe or critical COVID-19 a strong recommendation against using hydroxychloroquine
2. For adults with severe or critical COVID-19 a strong recommendation for using a short course of systemic corticosteroids
3. There is a weak recommendation to prefer dexamethasone as the steroid of choice
4. For adults with severe or critical COVID-19 not on a ventilator there is a weak recommendation to use remdesivir
5. For those on a ventilator there is a weak recommendation to not use remdesivir – this is based on lack of evidence in this setting
6. For adults with severe or critical COVID-19 a strong recommendation to use pharmacologic VTE prophylaxis
7. For adults with severe or critical COVID-19 without evidence of VTE a weak recommendation against using therapeutic anticoagulation
To access my free download area with 20 different resources to help you in your practice, go to pharmacyjoe.com/free.
If you like this post, check out my book – A Pharmacist’s Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies.
Leave a Reply